Divi's Laboratories and Laurus Labs lead India's record CRDMO growth, Jefferies says
BUZZ-Divi's Laboratories and Laurus Labs lead India's record CRDMO growth, Jefferies says ** Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS post CRDMO revenue growth of 86% and 50%, respectively, driven by strong execution and commercial manufacturing, the brokerage says, Jefferies says
** India's contract research and drug-making sector delivers record Q2 growth, with CRDMO revenue rising 31% year-on-year, Jefferies says
** Jefferies keeps DIVI's as its top pick and sees peptides as a key long-term growth opportunity
** Brokerage rates DIVI at "buy" with 12,550 rupees PT, while LAUL rated "hold" with 2,100 rupees PT
** Seven of nine covered companies beat expectations, supported by healthy client demand and order execution, the brokerage adds
** Management commentary remains upbeat on order visibility and client demand, Jefferies says
** DIVI up 72.5% YTD vs LAUL' 14% gain
(Reporting by Kashish Tandon in Bengaluru)
Recent news on Divi's Laboratories
See all newsDivi's Laboratories and Laurus Labs lead India's record CRDMO growth, Jefferies says
India Stocks: Indian shares inch higher to close at 8-month high as crude oil drops
India's Divi's Laboratories jumps to record high after profit jumps by nearly two thirds
Indian shares muted as markets pause after last week's rally
India Stocks: Indian shares consolidate in Diwali session after seven-day rally